Finance

HIV test maker announces 2004 financial guidance

Published in AIDS Weekly, November 17th, 2003

Calypte Biomedical Corporation (CYPT), the developer and marketer of the only two U.S. Food and Drug Administration (FDA) approved HIV-1 antibody tests for use with urine samples, announced financial guidance for its 2004 fiscal year ending December 31, 2004.

Based upon its current backlog, the company expects to generate revenues of $23 million to $25 million and net income of approximately $5 million. The company does not expect to pay taxes next year as a result of net operating loss carry forwards.

"We continue to generate growing interest in our urine HIV-1 EIA," said Tony Cataldo, Calypte Biomedical's chairman. "In just the last 3 months, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry